GSK plc (NYSE: GSK) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $39.50 price target on the stock, down previously from $53.00.
GSK plc (NYSE: GSK) was downgraded by analysts at Guggenheim from a "buy" rating to a "neutral" rating.
GSK Q3 Earnings Preview: Shingrix And Arexvy Make The Stock A 'Strong Buy' [Seeking Alpha]
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons